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Objectives Certain neointimal patterns including
neoatherosclerosis (NA) are known to be associated with poor
clinical outcome. The prevalence and time course of different
neointimal patterns have not been studied systematically. The
aim of this study was to investigate the serial changes in
neointimal pattern after drug-eluting stent implantation.
Patients and methods A total of 132 patients with 207
drug-eluting stents, who underwent two follow-up optical
coherence tomography studies at 6 and 12 months, were
included. Neointimal patterns were categorized as
homogeneous, heterogeneous, layered, or NA using optical
coherence tomography. Quantitative and qualitative
analyses of neointima were carried out.
Results Both at 6 and at 12 months, the homogenous
neointima was the predominant type (>75%), followed by
the layered and the heterogeneous pattern. At 12 months,
progression to NA was observed in 0.6% of the patients in
the homogeneous group, in 5.6% of the patients in the
heterogeneous group, and in 3.9% of the patients in the
layered group. Regression to the homogeneous pattern was
observed in 5.6% of the patients in the heterogeneous
group and 11.5% of the patients in the layered group.
Conclusion The homogenous neointima is the
predominant pattern both at 6 and at 12 months. The
neointimal pattern changed between 6 and 12 months in
10.6% of stents. Further studies are needed to understand
the mechanisms of these neointimal changes and their
clinical significance. Coron Artery Dis 28:557–563 Copyright
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Introduction
In-stent neoatherosclerosis (NA) is recognized as one of the
major contributing factors toward late stent failure that also
include very late stent thrombosis and in-stent restenosis
[1–3]. Recently, Taniwaki et al. [4] reported that NA was
found in 27.6% of very late stent thrombosis cases. The
incidence of NA in second-generation drug-eluting stent
(DES) has been reported to be comparable to that in first-
generation DES [5,6]. Moreover, NA was also observed
even after implantation of a bioresorbable scaffold [7,8].
Therefore, NA is still one of the major concerns after stent
implantation. Several studies previously reported predictors
of NA and the serial changes in neointima leading to NA
[2,6,9–12]. However, only a few studies have described the
serial change of neointima to a neointima pattern other than
NA. The aim of our study was to investigate the detailed
serial changes in neointimal patterns.
Patients and methods
Study population
Study participants were retrospectively selected from
the Massachusetts General Hospital (MGH) optical
coherence tomography (OCT) registry, which is an
international multicenter registry of patients who
underwent OCT of the coronary arteries and involves
20 sites across six countries (http://www.clinicaltrials.
gov:NCT01110538). The registry was approved by
the institutional review board at each participating
site. Written informed consent was obtained from all
patients before enrollment. For this study, we iden-
tify 137 patients treated with 213 DES, who had two
follow-up OCT imaging procedures at 6 months
(± 3 months) and 12 months (± 3 months). They also
had to have mean neointimal thickness more than
100 μm on at least three consecutive cross-sectional
images at a 1 mm interval at the 6-month follow-up.
Among these, five patients (six stents) who under-
went target lesion revascularization at the time of the
6-month follow-up were excluded (heterogeneous:
two stents, layered: four stents). Finally, 207 DES-
treated lesions from 132 patients were included in the
analysis. The reasons for the 12-month follow-up
were recurrent ischemia (N = 22) or scheduled
follow-up (N = 110).
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Optical coherence tomography image acquisition and
analysis
A frequency-domain OCT system (FD-OCT; C7-XR
OCT Intravascular Imaging System and ILUMIEN
OCT Intravascular Imaging Systems, St. Jude Medical,
St. Paul, Minnesota, USA) and a time-domain OCT
system (TD-OCT; M2/M3 Cardiology Imaging System,
LightLab Imaging Inc., Westford, Massachusetts, USA)
were used in this study. The technique of intracoronary
OCT imaging has been described previously [13]. All
images were digitally stored, deidentified, relabeled, and
submitted to MGH (Boston, Massachusetts, USA) for
analysis.
For serial comparisons, stents on the 6-month follow-up
were matched to those on the 12-month follow-up using
longitudinal landmarks such as side branches, calcium,
and stent edges. Cross-sectional OCT images were ana-
lyzed for qualitative and quantitative parameters. Lumen
and stent cross-sectional area (CSA) were measured at the
site of maximum neointimal hyperplasia and neointimal
CSA was calculated as the stent CSA minus the luminal
CSA. Neointimal CSA stenosis rate was calculated as
(neointimal CSA/stent CSA)× 100%. The neointimal
patterns were categorized as (i) homogeneous, a uniform
signal-rich band without focal variation or attenuation
(Fig. 1a); (ii) heterogeneous, nonuniform optical proper-
ties and various backscattering patterns (Fig. 1b);
(iii) layered, layers with different optical properties,
namely a luminal high scattering layer and adluminal low
scattering layer (Fig. 1c); and (iv) NA, lipid-laden
neointima (marked signal attenuation with a diffuse
border (Fig. 1d) [14–18]. Peri-strut low-intensity area
(PLIA) was defined as a region around the struts with
lower homogeneous intensity than the surrounding tissue
on OCT images without signal attenuation [19,20].
Macrophage infiltration was defined as increased signal
intensity accompanied by heterogeneous back shadows
as reported previously [21,22]. Neovascularization was
defined as small vesicular or tubular structures with a
diameter of 50–300 μm [15,16]. The thrombus was
defined as a mass protruding into the lumen and
dimension greater than 250 μm [16]. For serial compar-
ison, a quantitative assessment was performed using the
OCT off-line analysis software (St. Jude Medical). OCT
images were analyzed using off-line analysis software at
the MGH OCT Core Laboratory. All OCT images were
analyzed by two independent investigators who were
blinded to patient information. When there was dis-
cordance between the readers, a consensus reading was
obtained from a third independent investigator.
Statistical methods
Categorical variables were reported as n (%) and com-
pared using the χ2-test or Fisher’s exact test. Continuous
variables were expressed as mean ± SD or median and
interquartile range. Quantitative parameters were
compared using the paired t-test. Qualitative parameters
were compared using the McNemar test for the com-
parison between the 6-month and the 12-month follow-
ups. Statistical significance was defined as P value less
than 0.05. Statistical analyses were carried out using SPSS
18.0 (SPSS Inc., Chicago, Illinois, USA).
Results
Patient characteristics
At the 6-month follow-up, 162 (78.3%) stents were cate-
gorized as homogeneous and 18 (8.7%) stents were cate-
gorized as heterogeneous, 26 (12.6%) stents were
categorized as layered, and one (0.5%) stent was categorized
as NA. Clinical characteristics of the study population are
shown in Table 1. The median time interval from stent
implantation to the 6-month follow-up was 191 (142–203)
days and that to the 12-month follow-up was 376
(362–385) days.
Serial change of neointimal pattern
At the 12-month follow-up, 153 (73.9%) stents were cate-
gorized as a homogeneous group, 14 (6.8%) stents as het-
erogeneous, 36 (17.4%) stents as layered, and four (1.9%)
stents as NA. There was a trend toward a decrease in the
homogeneous (78.3–73.9%) and heterogeneous pattern
(8.7–6.8%) at the 12-month follow-up, whereas the layered
(12.6–17.4%) and NA (0.5–1.9%) patterns trended upward
(Fig. 2). The changes in the neointimal pattern are shown
in Fig. 3. Progression to a nonhomogeneous pattern was
observed in 8.0% of patients with a homogeneous pattern.
Progression to NA was observed in 0.6% of patients with a
homogeneous pattern and 4.5% of patients with non-
homogeneous patterns (5.6% of heterogeneous and 3.9% of
patients with a layered pattern) (P= 0.05). Also, progression
to a layered pattern was observed in 6.8% of patients with a
homogeneous pattern and 16.7% of patients with a het-
erogeneous pattern. However, progression to the hetero-
geneous pattern from the layered pattern was not detected,
and was observed only in 0.6% of patients with a homo-
geneous pattern. Regression to a homogeneous pattern was
observed in 9.1% of patients with nonhomogeneous
neointima (5.6% of patients with a heterogeneous pattern
and 11.5% of patients with a layered pattern). The one
stent with NA at the 6-month follow-up remained
unchanged at the 12-month follow-up. OCT parameters at
the 6-month and the 12-month follow-up time points are
shown in Table 2. Neointima CSA stenosis was sig-
nificantly greater and lumen area was smaller at the
12-month follow-up. The prevalence of PLIA decreased
significantly from the first to the 12-month follow-up. The
representative images are shown in Fig. 4.
Discussion
The main findings of this study are as follows:
(i) homogenous neointima is the predominant pattern
both at 6 and at 12 months, (ii) progression to non-
homogeneous neointima was observed in 8.0% of
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patients with homogenous neointima at 6 months,
(iii) progression to NA was observed in 0.6% of patients
with a homogeneous pattern and 4.5% of patients with
nonhomogeneous neointima at 6 months, and (iv)
regression to homogeneous neointima was observed in
9.1% of patients with nonhomogeneous neointima at
6 months.
Serial changes of the neointimal pattern
Previous studies reported that the proportion of homo-
genous neointima decreased and nonhomogenous
neointima including NA increased over time [12,23]. Kim
et al. [12] reported that 30.3% of patients with homo-
geneous neointima developed a nonhomogeneous pat-
tern from 9 months to 2 years. However, they categorized
neointima into homogeneous, heterogeneous (this group
included classical ‘heterogeneous’ and ‘layered’ patterns),
and lipid-laden patterns. Therefore, the difference between
heterogeneous and layered patterns remains unknown. Lee
and colleagues also reported changes in the neointimal pat-
tern and degree of neointimal hyperplasia. In lesions with
regression of neointima hyperplasia, conversion to a homo-
geneous pattern was observed in seven of eight patients with
heterogeneous neointima and progression to the layered
pattern or NA was not observed. In contrast, progression to
layered or NA intima was observed in lesions with progres-
sion of neointima [11]. However, the number of cases,
especially patients with nonhomogenous neointima, in this
study was quite small. Therefore, the serial changes in
neointima, in particular the changes in nonhomogeneous
neointima, are still unclear. Our data showed that homo-
geneous and heterogeneous patterns decreased and layered
Fig. 1
Representative optical coherence tomography images of different neointimal patterns. (a) Homogeneous pattern, a uniform signal-rich band without
focal variation or attenuation; (b) Heterogeneous pattern, nonuniform optical properties and various backscattering patterns; (c) Layered pattern,
layers with different optical properties, namely, a luminal high scattering layer and adluminal low scattering layer with a visible stent strut;
(d) neoatherosclerosis (NA), lipid-laden neointima with an invisible stent strut.
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and NA patterns increased between 6 months and 1 year.
Specifically, 6.8% of patients with a homogeneous pattern
and 16.7% of patients with heterogeneous patterns at
6 months developed a layered pattern at 12 months, and
0.6% of patients with a homogeneous pattern, 5.6% of
patients with a heterogeneous pattern, and 3.9% of patients
with layered patterns at 6 months developed NA. The nat-
ure of OCT dark appearance (low intensity) areas observed
in layered or heterogeneous neointima has been studied.
Nakano et al. [24] reported that excessive inflammation,
fibrin accumulation, and organized thrombus showed a
similar dark appearance in OCT. Shibuya et al. [25] also
reported that low-intensity areas with diffuse borders and
visible strut in OCT were a proteoglycan-rich myxomatous
matrix. Mixtures of these tissues and fibrous tissue create a
heterogeneous or a layered pattern. Accurate differentiation
of these components on OCT is not possible. Recently, a
pathology study reported that both heterogeneous and
Table 1 Patient characteristics at the 6-month follow-up
Clinical variables
Age (years) 58.2 ±9.8
Male 100 (75.8)
BMI (kg/m2) 24.8 ±2.7
Hypertension 82 (62.6)
Diabetes mellitus 55 (42.0)
Dyslipidemia 107 (81.1)
Current smoker 34 (25.8)
Previous MI 42 (31.1)
Presentation
AMI 8 (6.1)
Unstable angina 47 (35.6)
Stable angina 77 (58.3)
Laboratory data
Total cholesterol (mg/dl) 150.6 ±53.1
LDL-cholesterol (mg/dl) 83.0 ±34.8
HDL-cholesterol (mg/dl) 43.4 ±15.0
Triglyceride (mg/dl) 132.7 ±109.6
Creatinine (mg/dl) 0.89 ±0.27










First-generation DES 181 (87.4)
Second-generation DES 26 (12.6)
Values are mean ±SD, n (%), or median (IQR).
ACEI, angiotensin-converting enzyme inhibitor; AMI, acute myocardial infarction;
ARB, angiotensin II receptor blocker; DES, drug-eluting stent; HDL, high-density
lipoprotein; LAD, left anterior descending artery; LCX, left circumflex artery;















Homogeneous Heterogeneous Layered Neoatherosclerosis
6 month FU
12 month FU
The prevalence of each neointima at the 6-month and the 12-month
follow-ups. There was a trend toward a decrease in the prevalence of
homogeneous and heterogeneous patterns at the 12-month follow-up
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The changes in neointimal patterns between the 6-month and the 12-month
follow-ups. Homogeneous patterns at the 6-month follow-up converted into
heterogeneous (0.6%), layered (6.8%), and neoatherosclerosis (NA) (0.6%)
at the 12-month follow-up. Heterogeneous patterns at the 6-month follow-up
converted into homogeneous (5.6%), layered patterns (16.7%), and NA
(5.6%) at the 12-month follow-up. Layered patterns at the 6-month follow-up
converted into homogeneous (11.5%) and NA (3.9%) patterns at the
12-month follow-up.
Table 2 Quantitative and qualitative optical coherence tomography





Lumen area (mm2) 5.5 ±2.5 5.1 ±2.4 <0.001
Stent area (mm2) 7.3 ±2.5 7.3 ±2.6 0.21
Neointimal area (mm2) 1.8 ±1.4 2.1 ±1.4 <0.001
Min NIT (µm) 104.8 ±117.3 119.4 ±117.2 0.06
Mean NIT (µm) 232.8 ±179.0 265.1 ±183.5 <0.001
Max NIT (µm) 364.2 ±256.5 419.4 ±280.4 <0.001
Neointimal CSA
stenosis (%)
25.6 ±18.6 30.6 ±18.6 <0.001
Qualitative
Neovascularization 45 (21.7) 52 (25.1) 0.19
Peri-strut low-intensity
area
97 (46.9) 36 (17.4) <0.001
Macrophage 1 (0.5) 3 (1.4) 0.16
Thrombus 10 (4.8) 13 (6.3) 0.41
Values are mean ±SD or n (%).
CSA, cross-sectional area; NIT, neointimal thickness.
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layered patterns correlated with more than one histological
pattern [26]. The outcome of different patterns of neointima
may be dictated by the predominant component within the
neointima. For example, fibrin, which is observed more
frequently in DES than in a bare-metal stent (BMS) [27],
generally disappears during follow-up [28]. However, pro-
teoglycan deposition, which promotes retention of lipopro-
tein, and infiltration of inflammatory cells such as
macrophages, lymphocytes, and giant cells contribute toward
the development of NA [29,30]. These cells may gradually
replace smooth muscle cells, resulting in changes in the
neointimal pattern and eventually the development of NA.
In the current study, progression from a layered to a het-
erogeneous pattern was not detected. A recent pathology
study reported that 59% of frames with a layered pattern
corresponded to healed rupture/erosion and 6% involved
neointimal calcification. However, 86% of frames with a
heterogeneous pattern showed hypersensitivity vasculitis
and 14% showed smooth muscle cells in a proteoglycan-rich
and collagen-rich tissue [26]. These findings may suggest
that layered pattern neointima might be more mature than
heterogeneous patterns. Therefore, changes from a layered
pattern to a heterogeneous pattern may not occur.
Progression to neoatherosclerosis
Progression to NA was observed in 0.6% of patients with
a homogeneous pattern, 5.6% of patients with a hetero-
geneous pattern, and 3.9% of patients with a layered
pattern at the 6-month follow-up. Previous studies
reported a higher incidence of NA compared with our
study. However, the follow-up duration of these studies
was longer than ours. This indicates that neoathero-
sclerotic changes that can be detected by OCT mainly
occur after 1 year. Although this could not be studied
because of small numbers of cases, different neointimal
patterns may reflect different underlying mechanisms of
development of NA. NA in BMS is typically manifested
as a lipid pool in a well-developed neointima, which is
rich in vascular smooth muscle cells, and apoptosis of
vascular smooth muscle cells is believed to be the
underlying cause of NA [31]. However, NA in DES is
considered to be a direct consequence of delayed artery
healing with macrophage infiltration and apoptosis.
Indeed, NA with restenosis was found in no more than
20% of the entire NA population with DES [3]. In
addition, our group previously reported the association
between the degree of neointima hyperplasia and the
incidence of NA [32]. The incidence of NA was higher in
DES than in BMS in the early phase, despite thinner
neointima. In addition, heterogeneous neointima had
thinner neointima than layered pattern neointima (mean
neointimal thickness 347.1 vs. 533.9 μm, P< 0.001). As
mentioned above, fibrin deposition, which suggests
delayed arterial healing in DES, was found in hetero-
geneous pattern neointima. Indeed, the presence of
fibrin was more frequently observed and the degree of
Fig. 4
Representative images of the change of neointimal pattern. (A-1–D-1) Images at 6-month follow-up. (A-2–D-2) The corresponding images at the
12-month follow-up. (a) From a heterogeneous to a homogeneous pattern; (b) from a heterogeneous pattern (arrowhead) to a neoatherosclerosis
pattern (arrow); (c) from a layered pattern (arrowhead) to a homogeneous pattern; and (d) from a layered pattern (arrowhead) to a neoatherosclerosis
(arrow) pattern.
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neointima hyperplasia was significantly smaller in het-
erogeneous than in layered patterns in the validation
study in the swine model [33]. Heterogeneous neointima
that has relatively thin neointima might be closely asso-
ciated with the process leading to NA in DES.
Regression to a homogeneous pattern
Conversion to a homogeneous pattern was observed in
5.6% of patients with heterogeneous neointima and of
11.5% of patients with layered pattern neointima.
Homogeneous pattern neointima is mainly composed of
fibrous connective tissue and the conversion to a homo-
geneous pattern was considered to be the normal healing
process, and associated with a more favorable outcome
[33,34]. In addition, the prevalence of PLIA also
decreased from the 6-month follow-up to the 12-month
follow-up. PLIA also include dark appearance areas in
OCT, and the corresponding histologic tissues are
reported to be fibrin and the myxomatous extracellular
matrix including proteoglycan [20]. There are no objec-
tive criteria for the diagnosis of PLIA. Therefore, PLIA
might also partly overlap with heterogeneous and layered
patterns. As discussed above, dark appearance areas on
OCT may represent various tissues, and some of those
tissues may later be replaced by collagen fiber. Therefore,
the reversibility of those dark appearance areas on OCT
in early phases is not surprising. Because of the number of
cases, we could not study the factors associated with
regression or progression of neointima. A previous study
reported that NA is more common in patients with native
atherosclerosis progression [35]. Some other studies
reported that serum low-density lipoprotein levels and the
presence of chronic kidney disease are independent
predictors for NA [6,9,10]. One study reported that opti-
mal lipid-lowing therapy prevented conversion from
homogeneous to nonhomogeneous pattern intima [36].
These results suggest that not only focal vascular response
but also systemic factors might influence the changes in
the neointimal pattern. Further study is warranted to
determine the factors for predicting the changes in the
neointimal pattern and for understanding the association
between those changes in the neointimal pattern and
clinical outcomes.
Limitations
There are several limitations in this study. First, this is a
retrospective observational study. Second, stents with
severe in-stent restenosis at the 6-month follow-up were
excluded because new stents were implanted in these
cases and a 12-month follow-up study could not be per-
formed. Third, the follow-up period was short to detect
the serial change in NA. It is difficult to carry out a follow-
up OCT study after several years in completely asymp-
tomatic patients. Therefore, we used the data set that
included patients who underwent scheduled follow-up at
12 months. Fourth, the number of second-generation
DES in this study was small. Therefore, we could not
compare the different neointimal patterns between the
different DES types.
Conclusion
Most patients had homogenous pattern neointima both at
6 and at 12 months. In those with neointima thickness
greater than 100 µm at 6 months, 8.0% of homogenous
neointima progressed to a nonhomogeneous pattern and
9.1% of nonhomogeneous neointima converted into a
homogeneous pattern at 12 months. Further studies are
needed to understand the mechanisms of these neointi-
mal changes and their clinical significance.
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